Related Experiment Video

Updated: Jul 10, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Residual risk in statin-treated patients: future therapeutic options

Catherine Y Campbell1, Juan J Rivera, Roger S Blumenthal

  • 1Johns Hopkins Ciccarone Preventive Cardiology Center, Blalock 524C, 600 North Wolfe Street, Baltimore, MD 21287, USA.

Current Cardiology Reports
|November 15, 2007
PubMed

Insights

Statin therapy lowers cardiovascular risk, but high-risk patients often have residual coronary heart disease risk. Combination therapies may be needed for optimal cholesterol management and further risk reduction.

Area of Science:

  • Cardiology
  • Metabolic Disorders
  • Pharmacology

Background:

  • Statin therapy effectively reduces low-density lipoprotein cholesterol (LDL-C), cardiovascular morbidity, and mortality.
  • Despite maximal statin use, high-risk patients, including those with diabetes or metabolic syndrome, face significant residual coronary heart disease (CHD) risk.
  • Achieving optimal cardiovascular risk reduction often necessitates multifaceted treatment strategies beyond statins.

Purpose of the Study:

  • To highlight the persistent residual risk of coronary heart disease (CHD) in high-risk patient populations undergoing statin therapy.
  • To emphasize the need for comprehensive risk-reduction strategies in patients with specific comorbidities.
  • To discuss the role of combination therapy in achieving target lipid levels (LDL-C, HDL-C, non-HDL-C).

Main Methods:

  • Review of current clinical guidelines and evidence regarding statin therapy and residual cardiovascular risk.
  • Analysis of patient subgroups with elevated residual risk, including those with diabetes mellitus, low high-density lipoprotein cholesterol (HDL-C), and metabolic syndrome.
  • Discussion of the principles of combination therapy for managing dyslipidemia and other cardiovascular risk factors.

Main Results:

  • Maximal statin therapy does not eliminate residual CHD risk in many high-risk individuals.
  • Subgroups such as patients with diabetes, low HDL-C, or metabolic syndrome exhibit particularly high residual risk.
  • Aggressive, multi-component risk reduction, including combination lipid-lowering therapies, is frequently required.

Conclusions:

  • Residual cardiovascular risk remains a critical challenge even with optimal statin therapy.
  • Personalized and combination treatment approaches are essential for managing high-risk patients.
  • Targeting multiple lipid parameters (LDL-C, HDL-C, non-HDL-C) is crucial for comprehensive cardiovascular risk management.

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Therapeutic Drug Monitoring: Overview and Classification01:16

Therapeutic Drug Monitoring: Overview and Classification

Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...